Home › NDC Lookup › Ingredients › Neomycin Sulfate, Polymyxin B Sulfate, H... › 24208-0631-10
👂image loading
(from DailyMed)

Neomycin and Polymyxin B Sulfates and Hydrocortisone Neomycin Sulfate, 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL Solution/ Drops — NDC 24208-631-10 (Billing 24208-0631-10)

by Bausch & Lomb Incoporated · 1 BOTTLE, DROPPER in 1 CARTON / 10 mL in 1 BOTTLE, DROPPER

This is a package of Neomycin and Polymyxin B Sulfates and Hydrocortisone Neomycin Sulfate, 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL Solution/ Drops from Bausch & Lomb Incoporated, marketed since Dec 1995 and currently FDA-listed; retail pharmacies pay about $5.09 per mL (NADAC). It is this product's only package size.

NDC 24208-0631-10
🏷️ FDA NDC (as labeled) 24208-631-10 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Aug 27, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 24208-631-10
Product NDC 24208-631
11-digit billing NDC 24208063110
NCPDP billing unit ML — per mL (volume)
RxCUI 204423
UNII 057Y626693, 19371312D4, WI4X0X7BPJ
Application # ANDA064053
SPL Set ID 986e5b75-39fc-480f-9026-191b2d15dea1
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1995-12-29
Route AURICULAR (OTIC)
Dosage form SOLUTION/ DROPS
Substance NEOMYCIN SULFATE; POLYMYXIN B SULFATE; HYDROCORTISONE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 87991003102010
GPI class Neomycin-Polymyxin-HC
GCN Seq No 048557
GCN 14023
HICL code 003368
Ingredient (HICL) Neomycin/Polymyxin B/Hydrocort
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q8
Therapeutic class — intermediate (HIC2) Otic Preparations
HIC3 code Q8W
Therapeutic class — specific (HIC3) Ear Preparations,Antibiotics
AHFS code 08:12.28.28
AHFS class Polymyxin Antibiotics
FDB label name NEOMYCIN-POLYMYXIN-HC EAR SOLN
FDB brand name Neomycin-Polymyxin-Hydrocort
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 048557
  • GCN: 14023
  • GPI-14 (Medi-Span): 87991003102010
  • HICL (First Databank): 003368
  • AHFS class code: 08:12.28.28
  • RxCUI (RxNorm): 204423
Why two NDCs? The FDA registers this code as 24208-631-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 24208-0631-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, moderately potent (group II), Corticosteroids, potent (group III), Corticosteroids for local oral treatment
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NEOMYCIN-POLYMYXIN-HC EAR SOLN Ingredient Neomycin/Polymyxin B/Hydrocort

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $5.090 $50.90 / 10 ml
Medicaid paysCMS SDUD · 12 mo $5.93 $59.25 / 10 ml
Medicare drug plans payPart D · Q2 2026 $6.02 $60.24 / 10 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $5.937 $4.550
▼ Down 14% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
24208-0631-10 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 10 mL in 1 BOTTLE, DROPPER 1995-12-29 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [iU]/mL; 10 mg/mL 61314-0646-10 Sandoz 1 bottle $4.995 AT FDA listed save 2%
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mLthis 24208-0631-10 Bausch 1 bottle $5.090 AT Availability likely —
Neomycin And Polymyxin B Sulfates And Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 60219-2083-01 Amneal 1 bottle $5.090 AT Availability likely —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 50090-0433-00 A-S 1 bottle — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 63187-0270-10 Proficient 1 bottle — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [iU]/mL; 10 mg/mL 63187-0568-10 Proficient 10 ml — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 10 mg/mL; 3.5 mg/mL; 10000 [iU]/mL 68071-2735-01 NuCare 10 ml — AT Discontinued —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 68071-4174-01 NuCare 10 ml — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 70518-0763-00 REMEDYREPACK 1 bottle — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 76420-0104-10 Asclemed 10 ml — AT FDA listed —
Neomycin and Polymyxin B Sulfates and Hydrocortisone 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL 85766-0249-10 Sportpharm 1 bottle — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1995
On the market since
Dec 1995
📍
2026
Currently FDA-listed
31 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LRX7AJ16DT
    A blue mineral compound containing copper and sulfate. It's occasionally used as a colorant and preservative in some pharmaceutical and cosmetic preparations to maintain product stability and appearance.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 65OE787Q7W
    Potassium metabisulfite is a chemical salt used as a preservative and antioxidant in medicines and foods. It helps prevent spoilage and discoloration by protecting the product from oxidation and microbial growth.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBausch & Lomb Incoporated
Application holderBAUSCH AND LOMB INC
FDA applicationANDA064053 (ANDA)
Labeler code24208
First marketedDec 1995
Product typeHuman Prescription Drug
Portfolio2 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 25 words ▾

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics.

⏱️ Dosage and Administration 151 words ▾

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, four drops of the solution should be instilled into the affected ear 3 or 4 times daily.

For infants and children, three drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal.

Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the solution. This wick should be kept moist by adding further solution every 4 hours.

The wick should be replaced at least once every 24 hours.

⛔ Contraindications 49 words ▾

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (for example, herpes simplex virus or varicella zoster virus).

⚠️ Warnings ~1 min read ▾

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk of ototoxicity is greater with prolonged use; therefore, duration of therapy should be limited to 10 consecutive days (see PRECAUTIONS - General ). Patients being treated with eardrops containing neomycin should be under close clinical observation.

Due to its acidity, which may cause burning and stinging, neomycin and polymyxin B sulfates and hydrocortisone otic solution should not be used in any patients with a perforated tympanic membrane. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known.

Discontinue this product promptly if sensitization or irritation occurs. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifested simply as a failure to heal.

Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.

Contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

🤒 Adverse Reactions 175 words ▾

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B.

Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.

2 In another study, the incidence was found to be approximately 1%. 3 Skin hyperpigmentation has been reported with polymyxin B containing products. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Stinging and burning have been reported when this product has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 72 words ▾

Pregnancy Teratogenic Effects Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 55 words ▾

Pediatric Use The safety and effectiveness of neomycin and polymyxin B sulfates and hydrocortisone otic solution in otitis externa have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in otitis externa for pediatric patients under 2 years of age. 1

🧓 Geriatric Use 50 words ▾

Geriatric Use Clinical studies of neomycin and polymyxin B sulfates and hydrocortisone otic solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

🧬 Clinical Pharmacology 122 words ▾

CLINICAL PHARMACOLOGY Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. The anti-infective components in the combination are included to provide action against specific organisms susceptible to them.

Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae. The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.

📦 How Supplied / Storage and Handling 50 words ▾

HOW SUPPLIED Neomycin and polymyxin B sulfates and hydrocortisone otic solution, USP is supplied in a white plastic dropper bottle in the following size: 10 mL - NDC 24208-631-10 Storage: Store between 15°C to 25°C (59°F to 77°F). Securely tighten cap between uses. Keep out of reach of children. DoNotUSe

📋 Description 195 words ▾

DESCRIPTION Neomycin and polymyxin B sulfates and hydrocortisone otic solution, USP is a sterile antibacterial and anti-inflammatory solution for otic use. Each mL contains: Actives: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%); Inactives: propylene glycol, hydrochloric acid, potassium metabisulfite, cupric sulfate, glycerin, purified water. The pH range is 2.0 to 4.5.

Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis.

The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa, (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis.

The structural formulae are: Hydrocortisone, 11β, 17, 21 - trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: Schematic Description automatically generated with medium confidence Diagram Description automatically generated Diagram Description automatically generated

💬 Information for Patients 48 words ▾

Information for Patients Avoid contaminating bottle tip with material from the ear, fingers or other source. This caution is necessary if the sterility of the drops is to be preserved. If sensitization or irritation occurs, discontinue use immediately and contact your physician. Do not use in the eyes.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If the infection is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed. Treatment should not be continued for longer than 10 days.

Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly, gentamicin. Information for Patients Avoid contaminating bottle tip with material from the ear, fingers or other source. This caution is necessary if the sterility of the drops is to be preserved.

If sensitization or irritation occurs, discontinue use immediately and contact your physician. Do not use in the eyes. Laboratory Tests Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids. Pregnancy Teratogenic Effects Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women.

Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when neomycin and polymyxin B sulfates and hydrocortisone otic solution is used by a nursing woman.

Pediatric Use The safety and effectiveness of neomycin and polymyxin B sulfates and hydrocortisone otic solution in otitis externa have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in otitis externa for pediatric patients under 2 years of age. 1 Geriatric Use Clinical studies of neomycin and polymyxin B sulfates and hydrocortisone otic solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

🍼 Nursing Mothers 43 words ▾

Nursing Mothers Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when neomycin and polymyxin B sulfates and hydrocortisone otic solution is used by a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 23 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.

📄 Package Label / Principal Display Panel 30 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-631-10 Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution USP (Sterile) FOR USE IN EARS ONLY Rx only 10 mL BAUSCH + LOMB Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
165.1K
Units reimbursed last 4 qtrs
1.7M
Gross reimbursed last 4 qtrs
$9.82M
Avg / prescription
$59.48
Avg / unit
$5.9251
Latest quarter Q4 2025
32.5KRx
Medicaid pays / mL
$5.9251
gross reimbursed
vs
NADAC / mL
$5.0895
acquisition cost
=
Spread
+$0.8356
+16% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
33% FFS 67% MCO
Fee-for-service · 55,285 Rx Managed care · 109,830 Rx
State Medicaid map
Alaska: 750 units · 102 per 100k residents AK Maine: 6,064 units · 435 per 100k residents ME Washington: 33,830 units · 433 per 100k residents WA Idaho: 3,570 units · 182 per 100k residents ID Montana: 3,707 units · 327 per 100k residents MT North Dakota: 3,020 units · 386 per 100k residents ND Minnesota: 12,680 units · 221 per 100k residents MN Wisconsin: 21,590 units · 365 per 100k residents WI Michigan: 42,920 units · 428 per 100k residents MI New York: 134,990 units · 690 per 100k residents NY Vermont: 4,718 units · 729 per 100k residents VT New Hampshire: 2,150 units · 153 per 100k residents NH Oregon: 14,290 units · 338 per 100k residents OR Nevada: 15,340 units · 480 per 100k residents NV Wyoming: 740 units · 127 per 100k residents WY South Dakota: 2,301 units · 250 per 100k residents SD Iowa: 12,030 units · 375 per 100k residents IA Illinois: 46,688 units · 372 per 100k residents IL Indiana: 24,585 units · 358 per 100k residents IN Ohio: 53,554 units · 454 per 100k residents OH Pennsylvania: 64,924 units · 501 per 100k residents PA New Jersey: 68,696 units · 739 per 100k residents NJ Massachusetts: 22,966 units · 328 per 100k residents MA California: 234,283 units · 601 per 100k residents CA Utah: 3,930 units · 115 per 100k residents UT Colorado: 7,420 units · 126 per 100k residents CO Nebraska: 5,530 units · 280 per 100k residents NE Missouri: 31,375 units · 506 per 100k residents MO Kentucky: 36,061 units · 797 per 100k residents KY West Virginia: 7,300 units · 412 per 100k residents WV Virginia: 29,460 units · 338 per 100k residents VA Maryland: 25,480 units · 412 per 100k residents MD Connecticut: 15,890 units · 439 per 100k residents CT Rhode Island: 8,250 units · 753 per 100k residents RI Arizona: 32,521 units · 438 per 100k residents AZ New Mexico: 17,759 units · 840 per 100k residents NM Kansas: 4,670 units · 159 per 100k residents KS Arkansas: 13,060 units · 426 per 100k residents AR Tennessee: 22,520 units · 316 per 100k residents TN North Carolina: 41,655 units · 384 per 100k residents NC South Carolina: 20,340 units · 379 per 100k residents SC Delaware: 3,250 units · 315 per 100k residents DE Oklahoma: 1,310 units · 32.3 per 100k residents OK Louisiana: 30,910 units · 676 per 100k residents LA Mississippi: 18,243 units · 621 per 100k residents MS Alabama: 12,775 units · 250 per 100k residents AL Georgia: 34,045 units · 309 per 100k residents GA D.C.: 1,842 units · 271 per 100k residents DC Hawaii: 4,250 units · 296 per 100k residents HI Texas: 115,000 units · 377 per 100k residents TX Florida: 86,220 units · 381 per 100k residents FL
Units reimbursed · per 100k residents
32.3840
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 840 /100k
2 Kentucky 797 /100k
3 Rhode Island 753 /100k
4 New Jersey 739 /100k
5 Vermont 729 /100k
6 New York 690 /100k
7 Louisiana 676 /100k
8 Mississippi 621 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 24208-0630-05 · Bausch 24208-0635-62 · Bausch →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.